• Research Achievements
  • Current Clinical Trials

CHA Medical Group, a prominent leader in stem cell research

Currently, CHA Medical Group has17clinical trials ongoing at domestic and overseas sites.

Product. Indication F&D Pre-Clinical PhaseⅠ PhaseⅡ PhaseⅢ Note
Embryonic Stem Cells Pipelines
Retinal Pigment Epithelial Cells
Stargardt’s Macular Dystrophy (SMD) Technology transfer &
Partnership with US
Ocata Therapeutics, Inc.
Age-related Macular Degeneration (AMD)
Myopic Macular Degeneration (MMD)
Adult Stem Cells Pipelines
Placental Adherent Stromal Cells
Intermittent Claudication (IC) Technology transfer & Partnership with Israel Pluristem Therapeutics, Inc.
Umbilical Cord-derived Mescenchymal Stem Cells
Acute Cerebral Infarction
Disk Degeneration
Placenta-derived Mescenchymal Stem Cells
Alzheimer's Disease
Global Cerebral Ischemia Investigator Initiated Trial
Adipose-derived Mescenchymal Stem Cells
Articular Cartilage Injury
Disk Degeneration Investigator Initiated Trial
Rheumatoid Arthritis
Neural Progenitor Cells Parkinson's Disease Investigator Initiated Trial
Immunocytes Recurrent Glioblastoma Investigator Initiated Trial
Dendritic Cells